Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Lung Cancer

Free Subscription 01.12.2025 2 Am J Pathol 1 Ann Surg Oncol 4 BMC Cancer 2 Br J Cancer 1 Cancer Chemother Pharmacol 3 Cancer Lett 1 Cancer Res 1 Cancer Sci 1 Carcinogenesis 10 Clin Lung Cancer 1 Eur J Cancer 2 Eur J Cardiothorac Surg 1 Genes Chromosomes Cancer 1 Int J Cancer 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 2 J Cancer Res Clin Oncol 1 J Surg Oncol 1 JAMA Oncol 1 Lancet Oncol 3 Lung Cancer 1 Mol Carcinog 2 Oncogene 1 Oncologist 2 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. DING Y, Zhang H, Wen H, Zhao S, et al
   Single-Cell and Spatial Transcriptomics-Based Research Reveals Association Between M2a Macrophages and Tumor Spread through Air Spaces in Lung Adenocarcinoma.
   Am J Pathol. 2025;195:2477-2491.
   PubMed         Abstract available
   
   
2. DAS A, Tomita N, Syme KJ, Ma W, et al
   Cross-Modality Learning for Predicting Immunohistochemistry Biomarkers from Hematoxylin and Eosin-Stained Whole Slide Images.
   Am J Pathol. 2025;195:2400-2410.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. YAN H, Niimi T, Matsunaga T, Fukui M, et al
   ASO Visual Abstract: Personalized Surgical Decision-Making Model for Clinical Stage IA Pure-Solid Non-Small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Nov 28. doi: 10.1245/s10434-025-18787.
   PubMed        
   
   

   
   BMC Cancer

4. WU CH, Wu X, Hu X, Kennedy A, et al
   Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): significance in diagnosis and treatment in Asian patients.
   BMC Cancer. 2025 Nov 22. doi: 10.1186/s12885-025-15295.
   PubMed        
   
   
5. LI F, Li F, Lu H, Zhao D, et al
   A comparative study on prognostic differences between men and women with non-small cell lung cancer across different antitumor treatment modalities.
   BMC Cancer. 2025;25:1802.
   PubMed         Abstract available
   
   
6. NAM JW, Kim SE, Lee KM, Jung YW, et al
   Association between body-mass index change and lung cancer risk in Korea: nested case-control study.
   BMC Cancer. 2025;25:1805.
   PubMed         Abstract available
   
   
7. LI Y, Xu R, Xian J, Wang Z, et al
   Development and validation of a predictive model for recurrence in postoperative patients with stage ?A1-?A non-small cell lung cancer.
   BMC Cancer. 2025 Nov 27. doi: 10.1186/s12885-025-15275.
   PubMed         Abstract available
   
   

   
   Br J Cancer

8. HUANG P, He S, Qi Z, Nijiati Y, et al
   ENO1 promotes cancer metastasis via stimulating metabolism reprogramming in osteosarcoma.
   Br J Cancer. 2025;133:1625-1639.
   PubMed         Abstract available
   
   
9. DAI S, Liu Y, Guo T, Luo H, et al
   Systemic activation and tissue infiltration of CD8 + CX3CR1 + T cells in non-small cell lung cancer treated with neoadjuvant immune checkpoint blockade.
   Br J Cancer. 2025 Nov 22. doi: 10.1038/s41416-025-03160.
   PubMed         Abstract available
   
   

   
   Cancer Chemother Pharmacol

10. YAN Y, Zheng X, Zhao X, Si X, et al
    Afatinib for a non-small cell lung cancer patient in hemodialysis: A case report and literature review.
    Cancer Chemother Pharmacol. 2025;95:112.
    PubMed         Abstract available
    
    

    
    Cancer Lett

11. KHAN MA, Khan P, Fatima M, Rehman AU, et al
    Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression.
    Cancer Lett. 2025;638:218160.
    PubMed         Abstract available
    
    
12. WANG P, Tang HXL, Song J, Yang Y, et al
    Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib.
    Cancer Lett. 2026;636:218100.
    PubMed         Abstract available
    
    
13. SHE L, Chen J, Liu JY, Liu JS, et al
    A two-stage genome-wide association study to identify novel genetic loci associated with irAEs in lung cancer patients received PD-1/PD-L1 inhibitors.
    Cancer Lett. 2025 Nov 22:218168. doi: 10.1016/j.canlet.2025.218168.
    PubMed         Abstract available
    
    

    
    Cancer Res

14. PAN L, Luo J, Nie C, Fan S, et al
    A Deep Learning Framework Integrating Tumor Microenvironmental Features Accurately Predicts Multiple Driver Gene Mutations in Lung Cancer Pathology Images.
    Cancer Res. 2025 Nov 25. doi: 10.1158/0008-5472.CAN-25-0582.
    PubMed         Abstract available
    
    

    
    Cancer Sci

15. 
    Correction to "Trametinib Overcomes KRAS-G12V-Induced Osimertinib Resistance in a Leptomeningeal Carcinomatosis Model of EGFR-Mutant Lung Cancer".
    Cancer Sci. 2025 Nov 24. doi: 10.1111/cas.70278.
    PubMed        
    
    

    
    Carcinogenesis

16. ZHANG Y, Huang C, Chen Y, Liu L, et al
    BRINP3 promotes lung adenocarcinoma by enhancing CLOCK-mediated transcriptional regulation of CRYZL1 and activating the AKT pathway.
    Carcinogenesis. 2025;46:bgaf039.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

17. YANG JC, Ahn MJ, Kim JH, Lee YG, et al
    Central Nervous System Outcomes of Lazertinib Treatment in EGFR-Mutated Advanced NSCLC: Pooled Analysis From LASER201 and LASER301.
    Clin Lung Cancer. 2025;26:642-650.
    PubMed         Abstract available
    
    
18. PAN H, Huang W, Yang W, Li L, et al
    Efficacy of Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma with Tumor Spread Through Air Spaces: A Multi-Center Real-World Study.
    Clin Lung Cancer. 2025;26:659-670.
    PubMed         Abstract available
    
    
19. APHALE P, Dokania S, Shekhar H
    Letter to the Editor: "Prognostic Implications of Lymph Node Status in Non-Small-Cell Lung Cancer Patients Before and After Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Study".
    Clin Lung Cancer. 2025;27:47-48.
    PubMed        
    
    
20. YANG JC, Chen YM, Batra U, Do KH, et al
    Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial.
    Clin Lung Cancer. 2025;27:38-46.
    PubMed         Abstract available
    
    
21. KATCHER JG, Shusted CC, Bhatt P, Ruane BM, et al
    Brief Report: Lung Cancer Diagnoses among Lung Cancer Screening Program Participants With Family History of Lung Cancer.
    Clin Lung Cancer. 2025;27:34-37.
    PubMed        
    
    
22. ZURERA M, Laguna JC, Mezquita L, Higuera O, et al
    Germline Mutation Analysis and Real-World Impact in a Selected Cohort of Patients with Non-Small Cell Lung Cancer: INHERITY LC Study.
    Clin Lung Cancer. 2025 Nov 1:S1525-7304(25)00270.
    PubMed         Abstract available
    
    
23. GREGERSEN CH, Aggerholm-Pedersen N, Sandfeld-Paulsen B, Winther-Larsen A, et al
    Advanced Lung Cancer Inflammation Index has Prognostic Impact in Stage I Non-Small Cell Lung Cancer: A Registry-Based Analysis of 934 Patients.
    Clin Lung Cancer. 2025;27:24-33.
    PubMed         Abstract available
    
    
24. GAO M, Nie Y, Wang T, Jing F, et al
    Immune Checkpoint Inhibitor Without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A Real-World Retrospective Study.
    Clin Lung Cancer. 2025;26:e735-e742.
    PubMed         Abstract available
    
    
25. SUN Y, Yang D, Huang Z, Yan H, et al
    Clinical Outcomes of Patients With Advanced ALK-Rearranged Lung Squamous Cell Carcinoma Treated With ALK Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2025;26:617-625.
    PubMed         Abstract available
    
    
26. FILIPPI AR, Rulli E, Signorelli D, Willmann J, et al
    Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After
    Clin Lung Cancer. 2025;26:e633-e638.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

27. SMOLENSCHI C, Boileve A, Vaflard P, Watson S, et al
    Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: A French experience.
    Eur J Cancer. 2025;231:116066.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

28. PRISCIANDARO E, Bertolaccini L, Passani S, Szanto Z, et al
    Predictors of Thirty-Day Morbidity and Unplanned Readmission after Induction Therapy Followed by Lung Resection for Non-Small Cell Lung Cancer: European Society of Thoracic Surgeons Database Analysis.
    Eur J Cardiothorac Surg. 2025 Nov 27:ezaf426. doi: 10.1093.
    PubMed         Abstract available
    
    
29. NACHIRA D, Congedo MT, Calabrese G, Senatore A, et al
    Oncological and surgical outcomes of left trisegmentectomy or lingulectomy versus upper lobectomy for early stage Non-Small Cell Lung Cancer: a multicenter Study.
    Eur J Cardiothorac Surg. 2025 Nov 26:ezaf427. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

30. LIN F, Zhao M, Wu Q, Wu W, et al
    Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.
    Genes Chromosomes Cancer. 2025;64:e70088.
    PubMed         Abstract available
    
    

    
    Int J Cancer

31. CABRERA MO, Ten Haaf K, Borras JM, Font R, et al
    Impact of lung cancer screening eligibility criteria on participants' characteristics and healthcare resources.
    Int J Cancer. 2025 Nov 24. doi: 10.1002/ijc.70263.
    PubMed         Abstract available
    
    

    
    Int J Oncol

32. LIU L, Yang L, Li H, Shang T, et al
    The tumor microenvironment in lung cancer: Heterogeneity, therapeutic resistance and emerging treatment strategies (Review).
    Int J Oncol. 2026;68:11.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

33. HOU Q, Parpia S, Wierzbicki M, Kundapur V, et al
    Quality of Life of Stereotactic vs. Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results from the XXXXXX trial.
    Int J Radiat Oncol Biol Phys. 2025 Nov 21:S0360-3016(25)06498.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

34. ZHENG Y, Jin Q
    The role and mechanisms of the HIF-1 signaling pathway in LC-COPD.
    J Cancer Res Clin Oncol. 2025;151:328.
    PubMed         Abstract available
    
    
35. YU Z, Yang X, Wu J, Yu X, et al
    Surgical resection for pulmonary metastases from head and neck adenoid cystic carcinoma: a propensity-matched survival analysis.
    J Cancer Res Clin Oncol. 2025;151:330.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

36. MIKUBO M, Tamagawa S, Kondo Y, Sonoda D, et al
    Clinical Significance and Preoperative Prediction of High-Grade Subtypes in Early-Stage Lung Adenocarcinoma Eligible for Sublobar Resection.
    J Surg Oncol. 2025;132:1407-1415.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

37. AHN BC, Kim YJ, Lee Y, Suh KJ, et al
    Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2025 Nov 26:e255097. doi: 10.1001/jamaoncol.2025.5097.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

38. DOUMA LH, van der Noort V, Lalezari F, de Vries JF, et al
    Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.
    Lancet Oncol. 2025;26:1676-1684.
    PubMed         Abstract available
    
    

    
    Lung Cancer

39. PHILLIPS WJ, Zhan LJ, Chowdhury D, Gill J, et al
    Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE).
    Lung Cancer. 2025;210:108840.
    PubMed         Abstract available
    
    
40. SHI D, Yan X, Liu J, Chen H, et al
    CAR-T cell therapy for the treatment of lung cancer: Current challenges and emerging therapeutic strategies.
    Lung Cancer. 2025;210:108849.
    PubMed         Abstract available
    
    
41. ANCEL J, Dewolf M, Nawrocki-Raby B, Durlach A, et al
    AXL expression to predict resistance to immunotherapy in metastatic non-small cell lung cancer.
    Lung Cancer. 2025;210:108853.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

42. CHEN Y, Yu Y, Sun Q, Zhu X, et al
    Helicobacter pylori Infection, Metabolomic Signature and Extra-gastric Cancer Risk: A Mediation and Mendelian Randomization Analysis.
    Mol Carcinog. 2025;64:2086-2101.
    PubMed         Abstract available
    
    

    
    Oncogene

43. WU Z, Wang M, Dong X, Sun Y, et al
    The deubiquitinase OTUD1 orchestrates cisplatin chemosensitivity of non-small cell lung cancer through destabilizing RAD23B/XPC.
    Oncogene. 2025 Nov 24. doi: 10.1038/s41388-025-03647.
    PubMed         Abstract available
    
    
44. LIU T, Zuo X, Sun S, Du K, et al
    Overexpressed PRR11-SKA2-miR301a/454 bidirectional transcription unit essentially and coordinately promotes PI3K-AKT pathway activation and lung cancer progression.
    Oncogene. 2025 Nov 27. doi: 10.1038/s41388-025-03607.
    PubMed         Abstract available
    
    

    
    Oncologist

45. 
    Retraction of: Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
    Oncologist. 2025;30:oyaf364.
    PubMed        
    
    

    
    Semin Oncol

46. ZHENG M
    Sex-differential responses to immune checkpoint inhibitors across the disease continuum unified by tumor mutational burden.
    Semin Oncol. 2025;52:152414.
    PubMed         Abstract available
    
    
47. AIBANI R, Collins J, Borna AK, Kamran A, et al
    Comparative efficacy of osimertinib with and without radiation therapy in EGFR-mutated nonsmall cell lung cancer with brain metastases.
    Semin Oncol. 2025;53:152436.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.